The stock of bluebird bio Inc (NASDAQ:BLUE) is a huge mover today! About 2.28 million shares traded hands or 78.13% up from the average. bluebird bio Inc (NASDAQ:BLUE) has risen 32.57% since April 26, 2016 and is uptrending. It has outperformed by 27.31% the S&P500.
The move comes after 5 months positive chart setup for the $2.28B company. It was reported on Nov, 29 by Barchart.com. We have $66.92 PT which if reached, will make NASDAQ:BLUE worth $68.40 million more.
Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on February, 22. They expect $-1.84 EPS, down 42.64% or $0.55 from last year’s $-1.29 per share. After $-2.07 actual EPS reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -11.11% EPS growth.
bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage
Out of 14 analysts covering bluebird bio (NASDAQ:BLUE), 10 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 71% are positive. bluebird bio has been the topic of 29 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Roth Capital given on Thursday, December 3. Leerink Swann initiated the shares of BLUE in a report on Wednesday, February 3 with “Outperform” rating. The firm has “Buy” rating by Roth Capital given on Friday, August 28. The rating was initiated by Stifel Nicolaus on Thursday, December 17 with “Buy”. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Outperform”. The rating was maintained by Maxim Group with “Buy” on Thursday, September 29. The firm has “Neutral” rating by Bank of America given on Monday, December 7. TH Capital initiated the shares of BLUE in a report on Thursday, December 3 with “Buy” rating. On Friday, October 14 the stock rating was maintained by Leerink Swann with “Outperform”. As per Tuesday, September 8, the company rating was initiated by Morgan Stanley.
According to Zacks Investment Research, “Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.48 in 2016 Q2. Its up 0.48, from 1 in 2016Q1. The ratio increased, as 29 funds sold all bluebird bio Inc shares owned while 52 reduced positions. 20 funds bought stakes while 61 increased positions. They now own 42.29 million shares or 3.30% more from 40.94 million shares in 2016Q1.
Highlander Mngmt Ltd holds 1,500 shares or 0.06% of its portfolio. Glob X Mgmt Ltd Liability accumulated 0% or 90 shares. Westpac holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 36,500 shares. Fred Alger Mngmt has 0.01% invested in the company for 27,779 shares. Vanguard has invested 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Goldman Sachs accumulated 155,086 shares or 0% of the stock. Guggenheim Cap Limited Liability Company accumulated 0.01% or 75,772 shares. Financial Bank Of America De has 130,101 shares for 0% of their US portfolio. Emerald Mutual Fund Advisers Tru last reported 153,610 shares in the company. Jefferies Grp Limited Company holds 1,493 shares or 0% of its portfolio. Geode Mngmt Limited Liability Co reported 268,368 shares or 0.01% of all its holdings. The United Kingdom-based Barclays Public Limited Company has invested 0% in bluebird bio Inc (NASDAQ:BLUE). Profund Advsr Limited Liability Com last reported 20,953 shares in the company. Royal Comml Bank Of Canada holds 0% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 900 shares. Ghost Tree Ltd Co reported 170,000 shares or 2.13% of all its holdings.
More recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Fool.com which released: “Why bluebird bio Inc. Got Knocked Down Today” on November 03, 2016. Also Fool.com published the news titled: “Why bluebird bio Inc. Stock Jumped Today” on November 14, 2016. Fool.com‘s news article titled: “Why bluebird bio, Inc. Stock Got Crushed in October” with publication date: November 10, 2016 was also an interesting one.
BLUE Company Profile
bluebird bio, Inc., incorporated on April 16, 1992, is a biotechnology company. The Firm is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell immunotherapy. With its lentiviral gene therapies, T cell immunotherapy expertise and gene editing capabilities, it offers an integrated product platform with application in severe genetic and rare diseases, and in oncology. The Company’s gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. The Company’s oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. The Company’s oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.